Nivolumab Injection

FDA approved nivolumab (Opdivo Injection, Bristol-Myers Squibb Company), for the treatment of patients with metastatic non-small cell lung cancer (NSCLC) with progression on or after platinum-based chemotherapy. Patients with EGFR or ALK genomic tumor aberrations should have disease progression on FDA-approved therapy for these aberrations prior to receiving Opdivo. October 9, 2015 More Information: